Application of daclizumab as an immune induction therapy after liver transplantation

doi:10.3969/j.issn.2095-4344.2013.31.004

Abstract

Abstract:

BACKGROUND: Daclizumab can be specially combined with the inerleukin-2 receptor on the surface of activated T cells in human body, and this method can reflect the close of interleukin-2 receptor thus inferring the effect of induction therapy. At present, the daclizumab has been widely used in renal transplantation, but there is no consensus on its clinical application in liver transplantation.
OBJECTIVE: To investigate the expression of serum CD25+ T cells and soluble interleukin-2 receptor in the patients receiving daclizumab for liver transplantation during perioperative period.
METHODS: A total of 58 patients received orthotopic liver transplant for the first time were included and then the patients were randomly divided into two groups: control group (n=28) and treatment group (n=30). The patients in the two groups were treated with tacrolimus, mycophenolate mofetil and corticosteroids triple immunosuppressive regimen. The patients in the treatment group received immune induction therapy with daclizumab, and the patients in the control group did not receive daclizumab.
RESULTS AND CONCLUSION: Flow cytometry and enzyme-linked immunosorbent assay showed the expression levels of CD25+ T cells in the treatment group were significantly lower than those in the control group at different time points after liver transplantation (P < 0.01); and the expression levels of soluble interleukin-2 receptor in the treatment group were lower than those in the control group during transplantation and at the first day after transplantation (P < 0.05, P < 0.01). At 6 months after transplantation, the incidence of acute rejection was decreased in the treatment group (P < 0.01). The results indicate that daclizumab can effectively suppress the expression level of CD25+T cells, as well as the expression level of soluble interleukin-2 receptor in the peripheral blood in the early stage of liver transplantation, thus effectively reducing the rate of acute rejection.

Key words: organ transplantation, liver transplantation, daclizumab, CD25, soluble interleukin-2 receptor, immune induction, acute rejection

CLC Number:

R318

Liu Ying, Zhu Zhi-jun. Application of daclizumab as an immune induction therapy after liver transplantation[J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.2013.31.004.

Figures/Tables 2

References

[1] Schluns KS. Window of opportunity for daclizumab. Nat Med. 2011;17(5):545-547.

[2] Uemura T, Schaefer E, Hollenbeak CS, et al. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int. 2011;24(7):640-650.

[3] Post M, Raszeja-Wyszomirska J, Jarosz K, et al. Immunosuppression with low-dose daclizumab in liver transplant recipients with impaired kidney function: a single-center experience. Transplant Proc. 2009;41(8): 3107-3109.

[4] Zhang Y, Wen T, Yan L,et al. Following-up of a four-dose daclizumab induction therapy without calcineurin inhibitors in a liver transplantation recipient with severe renal dysfunction: a case report. Transplant Proc. 2008;40(10):3819-3820.

[5] Przepiorka D, Keman NA, Ippoliti C, et al. Daclizumab, a humanized Anti-interleukin-2 receptor alpha chain antibody, for treatment of acute Graft-versus-host disease. Am Soci Hematol. 2000;95(1):83-89.

[6] Foroncewicz B, Mucha K, Ryszkowska E, et al. Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center. Transplant Proc. 2009;41(8):3103-3106.

[7] Bingyi S, Ming C, Yeyong Q, et al. The effect of anti-CD25 monoclonal antibody (Simulect) to the lymphocytes in the peripheral blood of the recipients of kidney transplantation. Transplantation Proc. 2003;35(1):243-245.

[8] Sohrevardi SM, Azmandian J, Shafii Z, et al. Combination of a low dose of daclizumab and standard regimen for prevention of rejection in men and women receiving a kidney transplant. Iran J Kidney Dis. 2013;7(2):142-146.

[9] Hao WJ, Zong HT, Cui YS, et al. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis. Transplant Proc. 2012;44(10):2955-2960.

[10] State Council of the People's Republic of China. Administrative Regulations on Medical Institution. 1994-09-01.

[11] Church AC. Clinical advances in therapies targeting the interleukin-2 receptor. QJM. 2003;96(2):91-102.

[12] Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med. 2011; 17(5):604-609.

[13] Calmus Y, Kamar N, Gugenheim J, et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation. 2010;89(12):1504-1510.

[14] Eckhoff DE, McGuire B, Sellers M, et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation. 2000; 69(9):1867-1872.

[15] Sellers MT, McGuire BM, Haustein SV, et al. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center Analysis. Transplantation. 2004,78(8): 1212-1217.

[16] Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004;104(5):1559-1564.

[17] Hurst FP, Altieri M, Nee R, et al. Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction. Am J Nephrol. 2011;34(6):534-541.

[18] Ocampo C, Aristizabal A, Nieto J, et al. Induction therapies in kidney transplantation: the experience of Hospital Pablo Tobon Uribe, Medellín, Colombia 2005-2010. Transplant Proc. 2011;43(9):3359-3363.

[19] Saghafi H, Rahbar K, Nobakht Haghighi A, et al. Efficacy of anti-interleukin-2 receptor antibody (daclizumab) in reducing the incidence of acute rejection after renal transplantation. Nephrourol Mon. 2012;4(2):475-477.

[20] Koch M, Niemeyer G, Patel I, et al. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation. 2002;73(10):1640-1646.